Clinical Data CYTR expects to release its phase 3 data for using Aldoxorubicin to treat soft tissue sarcoma in July of 2016.
"The pivotal Phase 3 trial in STS is supported by positive Phase 2b data demonstrating a statistically significant improvement in PFS among STS patients receiving first-line treatment with aldoxorubicin compared to patients receiving treatment with doxorubicin, the current standard-of-care in this indication."